Neumora Therapeutics, Inc. NMRA

Company plans to submit an IND in the fourth quarter of 2026 and to initiate Phase 1 study by the end of 2026WATERTOWN, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today reported favorable pre-clinical toxicology results from NMRA-215, a potentially best-in-class, highly b

Neumora Therapeutics is back in focus after analysts cut their fair value estimate from US$8.91 to US$6.53 per share, a reduction of about 27% that resets expectations around the stock. Much of this shift tracks recent commentary on the decision to discontinue navacaprant, remove associated costs, and place more weight on the earlier stage pipeline, which bullish and bearish voices interpret very differently. As you read on, you will see how these updated targets fit into the evolving...

Neumora Therapeutics, Inc. (NASDAQ:NMRA) is among the best get rich quick stocks to buy right now. On June 18, Mizuho lowered the price target on Neumora Therapeutics, Inc. (NASDAQ:NMRA) to $4, down from $6. This came after the company’s negative Phase 3 KOASTAL-2 and -3 study outcomes. The firm has now removed navacaprant for depression from […]

We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. LB Pharmaceuticals Inc. (NASDAQ:LBRX) is one of the best up and coming stocks on our list. TheFly reported on May 28 that Clear Street maintained a Buy rating and a $45 price target for LBRX. The firm stated that […]

Neumora Therapeutics, Inc. (NASDAQ:NMRA) is one of the small-cap stocks with potential to rise 1000 percent. The company’s main near-term catalyst is navacaprant, an experimental depression treatment being tested in patients with major depressive disorder. On May 7, Neumora said two late-stage studies, KOASTAL-2 and KOASTAL-3, were fully enrolled in the first quarter of 2026, […]

The KOASTAL 2 and KOASTAL 3 trials also failed to meet their endpoints, with Neumora now culling development of the MDD candidate

Neumora’s stumble is the latest setback for a once-promising class of brain drugs. Elsewhere, a cell therapy manufacturing specialist took steps toward an IPO and J&J made its latest U.S investment.

Healthcare stocks declined late Monday afternoon with the NYSE Healthcare Index decreasing 0.6% and

Healthcare stocks declined Monday afternoon with the NYSE Healthcare Index dropping 0.7% and the Sta

The company described the results as disappointing and added that it is immediately discontinuing development of navacaprant.

Neumora Therapeutics (NASDAQ:NMRA) said on Monday that it will halt development of its experimental depression treatment navacaprant after two Phase III clinical studies failed to meet their primary efficacy goals. The drug candidate had been under evaluation as a potential treatment for patients suffering from major depressive disorder.